Emerging Trends and Growth Drivers in the Isocitrate Dehydrogenase (IDH) Inhibitors Market Through 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Isocitrate Dehydrogenase (IDH) Inhibitors Industry?
In recent times, the market size of isocitrate dehydrogenase (idh) inhibitors has experienced an unprecedented growth. The market, which was valued at $1.94 billion in 2024, is projected to reach $2.46 billion in 2025, growing at a compound annual growth rate (CAGR) of 27.0%. This remarkable growth during the historic period is owed to factors such as an increased prevalence of hematologic malignancies, advancements in genetic profiling for cancer, successful results of targeted therapies, initiatives in precision medicine, and an increased expenditure on healthcare in the field of oncology.
In the near future, the isocitrate dehydrogenase (idh) inhibitors market is speculated to witness significant growth. It’s predicted to increase to a value of $6.34 billion by the year 2029, at a compound annual growth rate (CAGR) of 26.7%. The anticipated growth during the forecast period is due to factors such as favorable reimbursement policies, an upswing in cases of blood cancers, heightened awareness of the disease among oncologists, increased use of precision medicine, and the expansion of healthcare infrastructure and specialized oncology centers. Key trends that are forecasted to shape the market include progress in genomic and molecular diagnostics, striking partnerships and licensing agreements, advancement in the technology used for drug delivery, enhancement in diagnostic tools, and the development of combination therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp
#Which Factors Are Currently Driving The Growth Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
The expected rise in acute myeloid leukemia instances is believed to spur the expansion of the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is a quick-developing blood and bone marrow cancer, signified by the accelerated generation of abnormal white blood cells that hamper the formation of normal blood cells. The aging population’s growth contributes to the ascending incidence of acute myeloid leukemia as older individuals have an elevated risk for this aggressive form of blood cancer due to alterations in their bone marrow and immune system linked with aging. Isocitrate dehydrogenase (IDH) inhibitors aid in acute myeloid leukemia treatment by inhibiting mutant IDH enzymes, thereby reinstating normal blood cell growth and inhibiting leukemia cell proliferation. For example, a report released by the Leukaemia Foundation, an Australia-based non-profit organization, in February 2023 stated that over 7,000 children, 6,000 young adults, and 108,000 adults aged between 25–65 are predicted to be diagnosed with blood cancers, mainly acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL) from 2022 to 2035. Hence, the frequency augmentation of acute myeloid leukemia is expected to accelerate the growth of the isocitrate dehydrogenase (IDH) inhibitors market.
How Is The Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Structured In Terms Of Segments?
The isocitrate dehydrogenase (IDH) inhibitors market covered in this report is segmented –
1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types
2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types
3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical
4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications
Subsegments:
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma
2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)
3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers
What Trends Are Currently Influencing Growth In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
Leading firms in the isocitrate dehydrogenase (IDH) inhibitors market are striving to receive regulatory approvals as a strategy to broaden the clinical application of their therapies, expedite their entry into the market, and gain an edge in treating IDH-mutant cancers. Regulatory approval is given by health departments and it gives a green light for a drug to be marketed and used once its safety and efficacy have been validated. For instance, in August 2024, the France-based pharmaceutical firm, Servier Laboratoires, obtained FDA approval for its VORANIGO (vorasidenib) tablets, which is the first targeted treatment for Grade 2 IDH-mutant glioma patients. The patients include those with astrocytoma and oligodendroglioma carrying IDH1 or IDH2 mutations. This orally administered therapy has been proven to significantly extend progression-free survival, as evidenced in the Phase 3 INDIGO trial. In the trial, patients showed a median progression-free survival rate of 27.7 months as compared to 11.1 months for the placebo group. VORANIGO provides a manageable, well-tolerated option with manageable side-effects, thereby marking a major breakthrough for a patient group that had few preceding treatment alternatives.
Who Are The Main Participants Shaping The Isocitrate Dehydrogenase (IDH) Inhibitors Market Landscape?
Major companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC
Get The Full Report Here:
Which Region Currently Holds The Largest Share In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24577&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
